Results 141 to 150 of about 134,214 (298)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

Global Diagnostics of Hemophilia and Bleeding Disorders: Insights From World Federation of Hemophilia International External Quality Assessment Scheme Program 2016–2023

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate laboratory diagnosis is essential for the effective management of bleeding disorders. The World Federation of Hemophilia (WFH) International External Quality Assessment Scheme (IEQAS) provides an international platform for comparative evaluation of laboratory performance.
Silmara de Lima Montalvão, Ian Jennings, Dianne P. Kitchen, Christopher Reilly‐Stitt, Glenn F. Pierce, Andreina Tovar, Jayson Martin, Assad Haffar, Steve Kitchen   +8 more
wiley   +1 more source

Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk. [PDF]

Front Cell Dev Biol
Willems RAL, Zanetto A, Campello E, Konings J, Bulato C, Kramer M, Russo FP, Roest M, Senzolo M, Burra P, Cate HT, de Vos-Geelen J, de Laat B, Simioni P, de Laat-Kremers R.   +14 more
europepmc   +1 more source

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Challenges in PT/INR harmonization across the total testing process. [PDF]

Biochem Med (Zagreb)
Zou JM, Li TJ, Liu Q, Hu YG.
europepmc   +1 more source

Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review

Haemophilia, EarlyView.
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson, Roy Khalife, Kelsey Uminski   +2 more
wiley   +1 more source

Hemostasis-Modulating Proteins from Indian Elapid and Viper Snake Venom: Mechanistic Insights and Therapeutic Opportunities. [PDF]

Life (Basel)
Kiruthika S, Sanju AV, Hussain SB, Nair BG, Vanuopadath M.   +4 more
europepmc   +1 more source

The Measurement of Prothrombin in Plasma [PDF]

Journal of Clinical Pathology, 1953
R, BIGGS, A S, DOUGLAS
openaire   +2 more sources

Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026

Haemophilia, EarlyView.
ABSTRACT Introduction Shared decision‐making regarding treatment choice in haemophilia care has become increasingly more complex and essential due to the availability of several innovative therapeutics that are characterized by their own advantages and limitations, which need to be tailored to individual patient needs.
Quentin Van Thillo, Guy Young, Cedric Hermans   +2 more
wiley   +1 more source